In a 2-center, phase I study (ESCaPE-CMD) evaluating the feasibility and safety of autologous CD34+ stem cells in patients with ANOCA and CMD, cell therapy improved CFR, angina frequency, angina class, and QoL.123. This evidence concerns the gene CD34 and angina pectoris.